Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Sorry, but I find it to hard not comment on this following quote:
"Only my opinion but I am not a trader and only know how to play the extremely long waiting game ..."
NO you don't know how to play the waiting game.
Anyone who knows that game, knows it takes patience.
And in my book they do not constantly moan.
But, that is maybe just my opinion.
I do not expect much movement on the information that IND has been submitted.
Reason is that having submitted the IND is no guarantee that is not contested.
I first see the real change coming when we are clinical.
At that point I expect a different kettle of investors to join, some with a lesser risk appetite then those us who is currently here.
Admittedly, I am disappointed that we did not get some money from the grant.
I too believed it was a shoe in at one stage.
But there is without a doubt a reason why we did not get it.
Could it be that HEMO applied but was unsuccessful?
Could it be that HEMO gave up on the application?
IF HEMO gave up, there could be several reasons for this, and just on the top of my head:
They decided to concentrate on IND as it was more cumbersome then anticipated. (But also where the real money is)
To many stipulations and restrictions to comply with if you get the grant.
Maybe they decided, it would be better to first apply in 2023.
Whatever the reason, it would have been nice if it had been explained in last week's annual report.
I don't think HEMOGENYX have applied.
Nothing was mentioned last week in the annual report and considering that it would have had to be applied for no later then a date in October 2022, I would have thought it prudent to inform us if they had applied last year.
I assume they have been too preoccupied with the IND application, which turned out to be a bit more cumbersome then first anticipated.
Maybe, HEMOGENYX will apply before the deadline in 2023, after a successful IND for HEMO CAR-T.
Yes, there was no material new information.
Which is good as in my view it would have to be RNS'ed.
It has been confirmed nothing has failed on the scientific level.
That is awesome itself.
But I really liked this comment "We expect to submit the IND application in the very near future."
VERY NEAR, I take that as mening before the end of May.
And more importantly it should not be rushed.
If there is like really positive news to be announced in the annual report this week, then I expect at least one RNS this week before the annual report is released.
But science cannot be rushed, if it was easy and there was no continuously problems to be solved, then any company could bring at least 4 new products on the market every year.
But science rarely is as straight forward like that.
So, as long as we are not told in the annual report that our candidates have been failures I am quite happy, as all that is needed from my side is further patience.
But admittedly, that is not what I am hoping for this week.
I would like to see the MF of a RNS that shocks the market and creates a stampede.
But that is all up to the markets appetite, should we get positive news.
@Matpr1
Please educate me.
How do you activate the green box system.
I hate to do so, as it is to akin to censorship for my liking.
But I am now to feed up with certain posters, they are simply wasting my time.
Please tell me how to activate the green box system.
Thanks in advance
@Dip666.
I am sorry to hear about your loss.
My deepest condolences to you and your family.
@HedgeHogarth
I saw this post of yours earlier today and it felt me with dread.
I would hate to see you go, as your contributions are much appreciated.
@FIREGUYUK
Thanks for highlighting that post.
And not least HedgeHogarth for writing such a good piece in the first place.
I don't think there is any room for moaning gits today, with such a response from Mr Sandler.
https://twitter.com/vmsandler/with_replies?lang=en-GB
I don't expect any news this week because today is still Passover and tomorrow is Friday, and we rarely get an RNS on a Friday.
Last year the Biodefense grant was announced before Passover, that has not been the case this year. Last year's date fell right in the middle of this year's Passover, so again we might not see or hear anything untill Passover ends (which is today), so again I do not really expect any news until next week.
I must say, that I find it utterly strange that the governor of New York has not clearly stated on what date the "winners" will be announced.
If I remember correctly it was clearly stated that the last day to submit an application was the 6-10-2022.
A good question is if HEMOGENYX felt they were in a good enough position to submit an application by that date.
Another question is if the restrictions about staying in New York for 3 years afterwards with CBR was found to be to restrictive?
Don't get me wrong, I think it would be great to get the grant, but there has been so little communication on the subject that the question hast to be raised: WAS IT EVEN APPLIED FOR?
I hope for no news until next tax year (which is upon us)
I hope for news on the grant first and foremost, weather it is positive or negative.
I would love not to hear that IND has been submitted, I'll much rather just hear out of the blue that we are now clinical.
Or even better yet, that FDA has accelerated the way to becoming clinical, because the groundwork is outstanding.
And then, I would like positive news on CBR.
This is my recipe for an explosive share price rise.
What's your dream scenario / recipe?
@JustHereForHemo
I love your take on a classic Kipling.
Well written for our circumstances.
I think Newmont would want to keep Havieron.
It might not be the biggest of their assets, but it is still a big find.
To me, it simply does not make sense to let a high quality go.
However, that does not mean that they do not make that choice.
And I for one, do hope that if decide to part with Havieron, that we get to be the buyer.
Even if we have to multiply our number of shares with 2, from either today's 5 Billion shares or what ever we end up with after a consolidation.
Part 2
But, let’s say that we don’t get to buy it outright (not because that is my desired scenario, but simply because it does not make sense to me why a 70% owner would let it go)
In a scenario where we do not get 100% of Havieron, but do get some good results from Scallywag, where will we see the biggest increase in mkt cap and thereby the share price.
In other words, which price point is most likely to be multiplied with 3 (just to pick a number)
20 Pence? (end result is in the 60 pence region)
Or
70 Pence? (end result is in the £2.10 region)
Part 1
Good afternoon everyone and thank you for your replies.
@MrChad, I am in full agreement with you, except I got the number to somewhere between 15-16 Billion shares in issue from today’s, 5 point something Billion shares. But that is just semantics, or maybe even worse, a miscalculation;-)
@Jerryspaniel, don’t you worry;-), I harbour no thoughts what so ever that GGP is on its way towards bankruptcy (although with higher dept, it automatically becomes a higher risk) And I have even less inclination to sell out in GGP.
GGP, under the leadership of Mr. Day is on the journey I have been arguing for, for years. Back in the early 2020, that did not seem to be the mainstream view or desire on this board.
Some may remember this link that I posted almost prolific back then:
https://stockhead.com.au/resources/this-is-how-3m-market-cap-minnow-ramelius-became-an-850m-gold-miner/
I am so pleased with the direction of GGP under the leadership of Mr. Day and what now seems to be the mainstream view on this board. WE ARE GOING MINING.
And it is always wonderful to attend the town hall meetings and meet follow investors who share this same desire.
And my feeling is many of us (you are excluded here, considering your holding:-) are just small fish, that have an ability to top on a monthly basis now a days.
So, with market psychology, most definitely playing a role in how we behave, I do think that the share price will have an effect on how high the mkt cap goes. (well obviously they are connected, they go hand in hand:-)
I just think that for smaller PI’s it really does matter whether we get 1 share or 3-5 shares per pound we invest on a regular basis, it has an effect on the cost per share and how much it has to rise before we recoup that expense.
In other words, for small PI’s we are more likely to be willing to keep continuously buying up from a consolidated price of 20 pence to 6o pence then we are from 80 pence to £2.40.
When we come up in that price region, then I think it is II’s that are going to take over, but how high are they willing to take it, assuming that they want to see a good return on their investment, here I am referring to dividends (which I know is a hot potato for you, as we have discussed that in the past), but that seemed to be one of possible several issues that cost Sandeep his job at Newcrest.
The magic number seems to be a consolidation of 10 from looking at the previous posts.
So that should bring the starting price after a consolidation up in the 70 pence region.
Over the next year, I believe our share price will be multiplied with an X factor, with all the news to come. Not least of first ore.
How many times it is going to be multiplied by, depends a lot on whether we get to buy Havieron outright or not.
At the Town Hall meeting Mr. Day said they we would need to consolidate the shares to reach the minimum criteria of 20 cent on ASX.
That criteria could be reached by just halving the number of shares in issue and leave us with shares in the region of 2.5 billion shares.
However, that number might float well in London, but is less likely to do so on the ASX and many other places in the world, accordingly to Mr. Day
Mr. Day suggested that a consolidation could happen with a number between 3 and 12.
He would take advice from the various brokers as to what the best price would be. Where the brokers see the biggest appetite, price wise.
Divided by either 12 or 3, that means we could end up in a scenario of some 420 million shares to 1.5 Billion shares in issue.
Or based on the current level of the share price. In a region of 21 pence to 84 pence.
The above numbers are just rough calculations. By no means are they exact, but it paints the picture well enough.
So, the question is: What is the magic number?
It’ does not matter how many shares are in issue, if the share price falls 10%, we lose 10% of the value of our investment.
But, I’ll argue that from a psychological point of view it matters a lot.
For me personally, when the share price falls from 7.7 pence to 7 pence, I have no care in the world.
But I know, I would not be able to say the same if the share price fell from 84 pence and down to 76 pence. That would really bother me, despite the fall being roughly around 10% in both cases.
Equally, psychologically the share price also has an effect on weather I want to buy or not.
I would not be equally keen to buy shares at 84 pence (consolidation by a factor of 12) compared to a share price of 21 pence (consolidation by a factor of 3).
And psychologically, I also think it is easier to triple the share price from a base of 21 pence compared with 84 pence when GGP hopefully strikes it big at Scallywag.
I am interested in hearing people’s thoughts.
What is your ideal number between 3 and 12 for consolidation and the resulting starting share price?
I am so looking forward to news on CBR.
Although it is not easily spread among humans, I'll still get a better night's sleep when we know CBR works.
(and of course it does)
A death rate above 50%, is no joke.
https://www.irishmirror.ie/news/irish-news/health-news/scientists-warn-caution-bird-flu-29350776.amp?fr=operanews
As far north as the appetite of the market allows.
And how far that is, well that is impossible to say as we simply do not know the markets appetite.
NO appetite what so ever and the share price will remain stagnant, hey it may even fall if there is an exodus of disappointed shareholders.
On the opposite end of the scale, if there all of a sudden is a wide interest from institutional Investors and other people who won't just flip the shares on a 30% profit, then I think that the share price could reach 10 to 20 pence.
And that is before we start talking about a positive announcement on CBR.
A patient at a hospital in Valencia might be infected with the Marburg virus.
This article claims it has a 88% mortality rate.
https://www.irishmirror.ie/lifestyle/travel/patient-isolated-hospital-after-deadly-29311841.amp?fr=operanews
We need a positive outcome from the CBR research taking place in the US, ASAP.